Literature DB >> 21098276

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Kutlu G Elpek1, Mark P Rubinstein, Angelique Bellemare-Pelletier, Ananda W Goldrath, Shannon J Turley.   

Abstract

Cytotoxic lymphocytes such as natural killer (NK) and CD8 T cells play important roles in immunosurveillance by killing virally infected or malignant cells. The homeostatic cytokine, IL-15, promotes the development, function, and survival of NK and CD8 T cells. IL-15 is normally presented in trans as a surface complex with IL-15 receptor-alpha-chain (IL-15Rα) by dendritic cells (DCs) and monocytes. Signaling by IL-15 occurs via the IL-2/IL-15 receptor β-chain (CD122) which is expressed primarily by NK1.1(+) cells and CD8 T cells. The use of preformed complexes of IL-15 with soluble IL-15Rα complexes to boost the effector function of CD122(+) cytolytic lymphocytes such as NK and CD8 T cells has recently gained considerable attention. Here we describe the impact of transient and prolonged in vivo stimulation by IL-15/IL-15Rα complexes on NK and CD8 T cells. Whereas transitory stimulation increased the number of activated NK cells and significantly enhanced their effector function, prolonged stimulation by IL-15/IL-15Rα complexes led to a marked accumulation of mature NK cells with considerably impaired activation, cytotoxicity, and proliferative activity, and an altered balance of activating and inhibitory receptors. In contrast to NK cells, CD8 T cells exhibited an activated phenotype and robust T cell receptor stimulation and effector function upon chronic stimulation with IL-15/IL-15Rα complexes. Thus, prolonged stimulation with the strong activating signal leads to a preferential accrual of mature NK cells with altered activation and diminished functional capacity. These findings point to a negative feedback mechanism to preferentially counterbalance excessive NK cell activity and may have important implications for cytokine immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098276      PMCID: PMC3003106          DOI: 10.1073/pnas.1012128107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

Review 3.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo.

Authors:  Christian A J Vosshenrich; Thomas Ranson; Sandrine I Samson; Erwan Corcuff; Francesco Colucci; Eleftheria E Rosmaraki; James P Di Santo
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

5.  Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2.

Authors:  J E Talmadge; R B Herberman; M A Chirigos; A E Maluish; M A Schneider; J S Adams; H Philips; G B Thurman; L Varesio; C Long
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Development of hyporesponsiveness of natural killer cells to augmentation of activity after multiple treatments with biological response modifiers.

Authors:  T Saito; R Ruffman; R D Welker; R B Herberman; M A Chirigos
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  The regulation and activation of CD44 by natural killer (NK) cells and its role in the production of IFN-gamma.

Authors:  Sarah L Sague; Cristina Tato; Ellen Puré; Christopher A Hunter
Journal:  J Interferon Cytokine Res       Date:  2004-05       Impact factor: 2.607

8.  Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection.

Authors:  Scott H Robbins; Marlowe S Tessmer; Toshifumi Mikayama; Laurent Brossay
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.

Authors:  Joyce Villanueva; Susan Lee; Edward H Giannini; Thomas B Graham; Murray H Passo; Alexandra Filipovich; Alexei A Grom
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

10.  Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect.

Authors:  H K Koblish; C A Hunter; M Wysocka; G Trinchieri; W M Lee
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  59 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

Review 2.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

3.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Authors:  John M Wrangle; Vamsidhar Velcheti; Manish R Patel; Elizabeth Garrett-Mayer; Elizabeth G Hill; James G Ravenel; Jeffrey S Miller; Mohammad Farhad; Kate Anderton; Kathryn Lindsey; Michele Taffaro-Neskey; Carol Sherman; Samantha Suriano; Marzena Swiderska-Syn; Amy Sion; Joni Harris; Andie R Edwards; Julie A Rytlewski; Catherine M Sanders; Erik C Yusko; Mark D Robinson; Carsten Krieg; William L Redmond; Jack O Egan; Peter R Rhode; Emily K Jeng; Amy D Rock; Hing C Wong; Mark P Rubinstein
Journal:  Lancet Oncol       Date:  2018-04-05       Impact factor: 41.316

Review 4.  Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals.

Authors:  Rosa Barreira da Silva; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

5.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

6.  NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.

Authors:  Natalija Simonović; Agnieszka Witalisz-Siepracka; Katrin Meissl; Caroline Lassnig; Ursula Reichart; Thomas Kolbe; Matthias Farlik; Christoph Bock; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  J Immunol       Date:  2019-02-04       Impact factor: 5.422

7.  Transcription factor Runx3 regulates interleukin-15-dependent natural killer cell activation.

Authors:  Ditsa Levanon; Varda Negreanu; Joseph Lotem; Karen Rae Bone; Ori Brenner; Dena Leshkowitz; Yoram Groner
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

8.  IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Authors:  Rossana Tallerico; Costanza M Cristiani; Elina Staaf; Cinzia Garofalo; Rosa Sottile; Mariaelena Capone; Yago Pico de Coaña; Gabriele Madonna; Eleonora Palella; Maria Wolodarski; Valentina Carannante; Domenico Mallardo; Ester Simeone; Antonio M Grimaldi; Sofia Johansson; Paolo Frumento; Elio Gulletta; Andrea Anichini; Francesco Colucci; Gennaro Ciliberto; Rolf Kiessling; Klas Kärre; Paolo A Ascierto; Ennio Carbone
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

9.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

10.  Agonist-selected T cell development requires strong T cell receptor signaling and store-operated calcium entry.

Authors:  Masatsugu Oh-Hora; Noriko Komatsu; Mojgan Pishyareh; Stefan Feske; Shohei Hori; Masaru Taniguchi; Anjana Rao; Hiroshi Takayanagi
Journal:  Immunity       Date:  2013-03-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.